Laurent P. Rivory - Publications, H-index & Citations

Laurent P. Rivory

Johnson & Johnson

37H指数

110论文数

4.8K被引数

收录论文 33

发表时间

Intended transcriptional silencing with siRNA results in gene repression through sequence-specific off-targeting 使用siRNA的预期转录沉默通过序列特异性脱靶导致基因抑制

RNA

IF5

2009-12-21

OAAI

Moses, Joshua; Goodchild, Amber; Rivory, Laurent P.

Comment on a published paper

BRITISH JOURNAL OF PHARMACOLOGY

IF7.7

2009-02-02

OAAI

Dodds, HM; Rivory, LP

Interfering ribonucleic acids that suppress expression of multiple unrelated genes

BMC BIOTECHNOLOGY

IF3.4

2009-01-01

OAAI

Passioura, Toby; Gozar, Mary M.; Goodchild, Amber; King, Andrew; Arndt, Greg M.; Poidinger, Michael; Birkett, Donald J.; Rivory, Laurent P.

Thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms and toxicity to capecitabine in advanced colorectal cancer patients

CLINICAL CANCER RESEARCH

IF10.2

2008-02-01

OAAI

Sharma, Rohini; Hoskins, Janelle M.; Rivory, Laurent P.; Zucknick, Manuela; London, Rosyln; Liddle, Christopher; Clarke, Stephen J.

Pemetrexed pharmacokinetics and pharmacodynamics in a phase I/II study of doublet chemotherapy with vinorelbine: implications for further optimisation of pemetrexed schedules

BRITISH JOURNAL OF CANCER

IF6.8

2007-10-02

OAAI

Li, K. M.; Rivory, L. P.; Clarke, S. J.

Cytotoxic G-rich oligodeoxynucleotides: putafive protein targets and required sequence motif

NUCLEIC ACIDS RESEARCH

IF13.1

2007-06-22

OAAI

Goodchild, Amber; King, Andrew; Gozar, Mary Margaret; Passioura, Toby; Tucker, Carly; Rivory, Laurent

Imatinib disposition and ABCB1 (MDR1, p-glycoprotein) genotype

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2007-05-09

131

PREAI

Gurney, H.; Wong, M.; Balleine, R. L.; Rivory, L. P.; McLachlan, A. J.; Hoskins, J. M.; Wilcken, N.; Clarke, C. L.; Mann, G. J.; Collins, M.; Delforce, S-E; Lynch, K.; Schran, H.

Inhibition of topoisomerase I cleavage activity by thiol-reactive compounds - Importance of vicinal cysteines 504 and 505

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2007-05-01

OAAI

Montaudon, Daniele; Palle, Komaraiah; Rivory, Laurent P.; Robert, Jacques; Douat-Casassus, Celine; Quideau, Stephane; Bjornsti, Mary-Ann; Pourquier, Philippe

Transcriptional repression of hepatic Cytochrome P450 3A4 gene in the presence of cancer

CLINICAL CANCER RESEARCH

IF10.2

2006-12-22

OAAI

Charles, Kellie A.; Rivory, Laurent P.; Brown, Sandie L.; Liddle, Christopher; Clarke, Stephen J.; Robertson, Graham R.

Altered deoxyuridine and thymidine in plasma following capecitabine treatment in colorectal cancer patients

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2006-07-07

OAAI

Li, Kong M.; Rivory, Laurent P.; Hoskins, Janelle; Sharma, Rohini; Clarke, Stephen J.

A phase II study of fixed-dose capecitabine and assessment of predictors of toxicity in patients with advanced/metastatic colorectal cancer

BRITISH JOURNAL OF CANCER

IF6.8

2006-03-21

OAAI

Sharma, R; Rivory, L; Beale, P; Ong, S; Horvath, L; Clarke, SJ

The in vitro metabolism of irinotecan (CPT-11) by carboxylesterase and β-glucuronidase in human colorectal tumours

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY

IF3

2005-08-05

OAAI

Tobin, Peter; Clarke, Stephen; Seale, J. Paul; Lee, Soon; Solomon, Michael; Aulds, Sally; Crawford, Michael; Gallagher, James; Eyers, Tony; Rivory, Laurent

Hepatic technetium Tc 99m-labeled sestamibi elimination rate and ABCB1 (MDR1) genotype as indicators of ABCB1 (P-glycoprotein) activity in patients with cancer

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2005-01-01

PREAI

Wong, M; Evans, S; Rivory, LP; Hoskins, JM; Mann, GJ; Farlow, D; Clarke, CL; Balleine, RL; Gurney, H

Inhibition of acetylcholinesterase in patients receiving irinotecan (camptothecin-II)

CLINICAL PHARMACOLOGY & THERAPEUTICS

IF5.5

2004-11-01

PREAI

Tobin, P; Rivory, L; Clarke, S